What type of drug is Quizartinib?

Quizartinib(Quizartinib) is a selective tyrosine kinase inhibitor that belongs to an important category of modern targeted therapy drugs. Its mechanism of action focuses on the FLT3 signaling pathway. FLT3 is a common oncogenic driver in acute myeloid leukemia (AML) and is significantly aberrantly activated in patients carrying internal tandem duplication (ITD) mutations. This mutation can continuously stimulate the proliferation and survival of leukemia cells, making the disease more aggressive and at risk of recurrence. Quizartinib blocks abnormal signaling by inhibiting FLT3 kinase activity, thereby inhibiting leukemia cell proliferation and promoting abnormal cell apoptosis.

In clinical applications, quizartinib is usually used in combination with standard chemotherapy regimens, including induction and consolidation therapy with cytarabine and anthracyclines. After completion of consolidation chemotherapy, quizartinib can be continued as single maintenance therapy with the goal of delaying or preventing relapse. Its precise targeting properties enable it to show specific therapeutic advantages in newly diagnosed FLT3-ITD-positive adult AML patients, providing a new treatment option for such high-risk patients.

Compared with traditional chemotherapy, the advantage of quizartinib is that it targets specific molecular targets, can reduce damage to non-target cells, and provides a more precise treatment strategy for high-risk leukemia patients. This targeted therapy model represents an important transition in AML treatment from empirical chemotherapy to molecular-oriented therapy, laying the foundation for future personalized and precision medicine. In addition, the use of quizartinib requires strict compliance with a monitoring plan, including assessment of cardiac function and blood routine, to ensure a balance between safety and efficacy.

In general, quizartinib is a tyrosine kinase inhibitor that targetsFLT3-ITD-positive AML. It provides new treatment options for high-risk patients by accurately intervening in the key growth signals of leukemia cells. It is one of the important drugs in the modern targeted therapy system.

Keyword tag: Quizartinib Drug type Kase inhibitor FLT3-ITD acute myeloid leukemia AML targeted therapy leukemia maintenance therapy

References:https://en.wikipedia.org/wiki/Quizartinib